New hope for rare gut disease? drug trial launches for APECED enteritis
NCT ID NCT07202598
First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 6 times
Summary
This phase 2 trial tests a drug called emapalumab in 10 people with APECED, a rare disease where the immune system attacks the body. The drug aims to reduce gut inflammation (enteritis) that causes severe symptoms. Participants receive 7 IV doses over 6 months, and researchers track symptom changes and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Emapalumab (a drug given by IV infusion)
- What this could lead to
- If it works, this could point toward a treatment for severe gut inflammation in people with APECED.
- What could go wrong
- This is a very small early-phase trial with only 10 people. It may not show clear benefit, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY ENTERITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States